Focal segmental membranoproliferative glomerulonephritis in children.
Eight patients with focal segmental membranoproliferative glomerulonephritis (FSMPGN) were followed for 5-16 years. Their urinary abnormalities were detected by school urinary screening in seven, and one patient presented with nephrotic syndrome. All but one patient were treated with alternate-day (ALD) prednisolone. With time, urinalysis became normal in six and two continued to have proteinuria with or without hematuria. Serum albumin, cholesterol, and creatinine levels were normal at the last follow-up. Serum C3 returned to normal levels in six, but remained persistently decreased in two. Mesangial proliferation and matrix changes in glomeruli without MPGN lesions were mild. Subendothelial and mesangial electron-dense deposits and deposits containing C3 along capillary walls and mesangium were observed. MPGN lesions and mesangial proliferation improved. No severe growth retardation was observed, but the duration and dosage of ALD prednisolone could be reduced further, since the patients with FSMPGN seemed to have an excellent prognosis.
Iitaka
Kikuo
K
Department of Pediatrics, Yamato City Hospital, 8-3-6 Fukaminishi Yamato-shi, Kanagawa 242-8602, Japan. kikuo.iitaka@gov.city.yamato.kanagawa.jp
Nakamura
Shinya
S
Moriya
Shunsuke
S
Motoyama
Osamu
O
Sakai
Tadasu
T
D000293:Adolescent; D001706:Biopsy; D002648:Child; D003176:Complement C3 / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D015432:Glomerulonephritis, Membranoproliferative / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage*; D011379:Prognosis; D016896:Treatment Outcome; D016482:Urinalysis
D003176:Complement C3; D005938:Glucocorticoids; D011239:Prednisolone; D003404:Creatinine